ALLK Allakos Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALLK

Price (delayed)

$4.71

Market cap

$403.56M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.06

Enterprise value

$362.29M

Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company's lead antibody, lirentelimab ...

Highlights
ALLK's EPS is up by 25% since the previous quarter
Allakos's debt has decreased by 6% YoY
The net income has contracted by 19% YoY but it has grown by 14% from the previous quarter
The equity has declined by 30% year-on-year and by 10% since the previous quarter
The company's quick ratio fell by 21% QoQ and by 12% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.allakos.com
Peers: OCUP

Key stats

What are the main financial stats of ALLK
Market
Shares outstanding
85.68M
Market cap
$403.56M
Enterprise value
$362.29M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.29
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$323.63M
EBITDA
-$313.65M
Free cash flow
-$287.14M
Per share
EPS
-$5.06
Free cash flow per share
-$4.54
Book value per share
$3.64
Revenue per share
$0
TBVPS
$6.11
Balance sheet
Total assets
$386.42M
Total liabilities
$75.99M
Debt
$45.95M
Equity
$310.43M
Working capital
$278.81M
Liquidity
Debt to equity
0.15
Current ratio
10.28
Quick ratio
9.31
Net debt/EBITDA
0.13
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-87.8%
Return on equity
-112.5%
Return on invested capital
-117.3%
Return on capital employed
-90.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALLK stock price

How has the Allakos stock price performed over time
Intraday
0.43%
1 week
-14.36%
1 month
-23.91%
1 year
-19.07%
YTD
-44.06%
QTD
-44.06%

Financial performance

How have Allakos's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$322.43M
Net income
-$319.95M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 19% YoY but it has grown by 14% from the previous quarter
The operating income has contracted by 19% YoY but it has grown by 13% from the previous quarter

Growth

What is Allakos's growth rate over time

Valuation

What is Allakos stock price valuation
P/E
N/A
P/B
1.29
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ALLK's EPS is up by 25% since the previous quarter
ALLK's price to book (P/B) is 82% less than its 5-year quarterly average of 7.2
The equity has declined by 30% year-on-year and by 10% since the previous quarter

Efficiency

How efficient is Allakos business performance
ALLK's return on equity has dropped by 125% year-on-year but it is up by 3.6% since the previous quarter
The return on assets has dropped by 103% year-on-year but it has grown by 5% since the previous quarter
The ROIC has plunged by 90% YoY but it has grown by 7% from the previous quarter

Dividends

What is ALLK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALLK.

Financial health

How did Allakos financials performed over time
Allakos's total assets has decreased by 28% YoY and by 8% from the previous quarter
The company's quick ratio fell by 21% QoQ and by 12% YoY
Allakos's debt is 85% less than its equity
ALLK's debt to equity is up by 36% YoY and by 7% from the previous quarter
The equity has declined by 30% year-on-year and by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.